RET Fusion Positive
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma (NCT02587650) | University of California, San Francisco | 2015-03-26 |
Track RET Fusion Positive automatically
Every clearance here is in the API, with alerts when new ones post.